Updated Results of Fumanba-1: A Phase 1b/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma
第一作者单位:[1]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Hematol, Wuhan, Peoples R China
推荐引用方式(GB/T 7714):
Li Chunrui,Wang Di,Fang Baijun,et al.Updated Results of Fumanba-1: A Phase 1b/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma[J].BLOOD.2022,140:7435-7436.doi:10.1182/blood-2022-166465.
APA:
Li, Chunrui,Wang, Di,Fang, Baijun,Song, Yongping,Huang, He...&Qiu, Lugui.(2022).Updated Results of Fumanba-1: A Phase 1b/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma.BLOOD,140,
MLA:
Li, Chunrui,et al."Updated Results of Fumanba-1: A Phase 1b/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma".BLOOD 140.(2022):7435-7436